ClinicalTrials.gg
CompletedNCT00840879Updated Aug 19, 2024Results posted

Meloxicam 15 mg Tablets Under Non-Fasting Conditions

A Phase 1 interventional study of Meloxicam 15 mg Tablets and Mobic® 15 mg Tablets in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare the rate and extent of absorption of meloxicam from a test formulation Meloxicam 15 mg Tablets versus the reference Mobic® 15 mg Tablets under fed conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking male or female with a minimum age of 18 years (i.e. non-smoker or non tobacco user for at least 90 days prior to pre-study medical).
  • (BMI = weight/height²) greater than or equal to 18.5 kg/m² and less than or equal to 29.9 kg/m².
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements, as evidenced by a signed Form.
  • Normal findings in the physical examination, 12-lead and vital signs (blood pressure between 100-140/60-90 mmHg, heart rate between 50-99 beats/min, temperature between 35.8ºC and 37.5ºC).
  • Negative for drugs of abuse, nicotine, alcohol, -surface antigen, and , and for female subjects, pregnancy (serum ß-CG).
  • No clinical laboratory values outside of the acceptable range as defined by BCR, unless the Principal Investigator decides they are not .
  • Female subjects who are surgically sterile for at least six months or for at least one year, or who will avoid pregnancy prior to the study, during the study and up until one month after the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Known history of to meloxicam (for example Mobic®), or related drugs such as any other non-steroidal anti-inflammatory drugs (NSAID) such as acetylsalicyclic acid (e.g. Excedrin®, Aspirin®), ibuprofen (e.g. Motrin®), celecoxib (e.g. Celebrex®), Feldene®, Indocin®, Naprosyn®, Vioxx®, Toradol®, Clinoril®, Tolectin®, or Lodine®.
  • Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, or liver disease, unless judged not by the Principal Investigator, or medical designate.
  • Any history or presence of peptic ulcer disease, gastrointestinal bleeding, or kidney disease.
  • Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Any clinically significant illness during the last four weeks prior to entry into this study.
  • Presence of any significant physical or organ abnormality.
  • Any subject with history of drug abuse.
  • Any psychiatric or psychological disease (including depression) unless deemed not clinically significant by the Principal Investigator, or medical designate.
  • Use of any prescription medication within 14 days preceding entry into this study.
  • Use of over-the-counter (OTC) medication within seven days preceding entry into this study (except for spermicidal/barrier products).
  • Female subjects: use of oral contraceptives or contraceptive implants (such as Norplant®) within 30 days prior to drug administration or a depot injection of progestogen drug (e.g. Depo-Provera®) within one year prior to drug administration.
  • Female subjects: presence of pregnancy or lactation.
  • Female subjects at risk of becoming pregnant must consent to using two medically acceptable methods of contraception throughout the entire study, including the and for one month after the completion of the study. Medically acceptable barrier methods of contraception that may be used by the subject and/or partner include diaphragm with spermicide, IUD, condom with foam, and vaginal spermicidal suppository. Complete abstinence can be used alone as a method of contraception.
  • Any subject who has had blood drawn within 56 days preceding this study, taken during the conduct of any clinical study at a facility other than BCR or within the lockout period specified by a previous study conducted at BCR.
  • Participation in a clinical trial with an drug within 30 days preceding this study.
  • Any subject who has donated blood within 56 days preceding this study.
  • Any subject who has participated as a plasma donor in a plasmapheresis program within seven days preceding this study.
  • Any subject with a recent (less than one year) history of alcohol abuse.
  • Significant or recent history of asthma (after 12 years of age), or familial history of asthma or aspirin-sensitive asthma, sever bronchospasm, nasal polyps or chronic sinusitis.
  • Intolerance to venipuncture.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Meloxicam

    Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period

    Drug: Meloxicam 15 mg Tablets

  • Active comparator
    Mobic®

    Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period

    Drug: Mobic® 15 mg Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Observed Concentration

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 96 hour period

  2. AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 96 hour period

  3. AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 96 hour period

07

Results

Posted Aug 4, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneMeloxicam (Test) FirstMobic® (Reference) First
Started1414
Completed1414
Not completed00
Washout: 14 Days
Participant flow — Washout: 14 Days
MilestoneMeloxicam (Test) FirstMobic® (Reference) First
Started1414
Completed1414
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneMeloxicam (Test) FirstMobic® (Reference) First
Started1414
Completed1314
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryCmax - Maximum Observed Concentration

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 96 hour period
Reported as:
Mean · µg/mL
Cmax - Maximum Observed Concentration
µg/mLMeloxicamMobic®
Cmax - Maximum Observed Concentration1.32 ± 0.221.36 ± 0.29
Statistical analysis
  • Meloxicam vs Mobic® · Test/ref ratio of ls means x 100: 98.15 · 90% CI 90.96 to 105.90Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 96 hour period
Reported as:
Mean · µg*h/mL
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
µg*h/mLMeloxicamMobic®
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)40.50 ± 15.8842.38 ± 17.62
Statistical analysis
  • Meloxicam vs Mobic® · Test/ref ratio of ls means x 100: 96.34 · 90% CI 91.82 to 101.07Bioequivalence is established when 90% Confidence Interval falls within 80-125.
PrimaryAUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 96 hour period
Reported as:
Mean · µg*h/mL
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
µg*h/mLMeloxicamMobic®
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)37.11 ± 12.3338.00 ± 12.70
Statistical analysis
  • Meloxicam vs Mobic® · Test/ref ratio of ls means x 100: 97.76 · 90% CI 93.31 to 102.42Bioequivalence is established when 90% Confidence Interval falls within 80-125.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Meloxicam (Test) FirstMobic® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years141428
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Meloxicam (Test) FirstMobic® (Reference) FirstTotal
Female8614
Male6814
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Meloxicam (Test) FirstMobic® (Reference) FirstTotal
Caucasian81321
Black415
Asian202
Region of Enrollment
Region of Enrollment(participants)Meloxicam (Test) FirstMobic® (Reference) FirstTotal
Canada141428
08

Study locations

1 site
  • Biovail Contract Research
    Toronto, Ontario M1L4S4, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Feb 2004 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2009
First posted
Feb 10, 2009
Start
Feb 2004
Primary completionActual
Feb 2004
CompletionActual
Feb 2004
Results first posted
Aug 4, 2009
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00840879
First posted
Feb 10, 2009
Start date
Feb 2004
Primary completion
Feb 2004
Completion
Feb 2004
Results posted
Aug 4, 2009
Last update
Aug 19, 2024

Study contacts

Paul Y. Tam, M.D.
principal investigator · Biovail Contract Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion